We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+54.07%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$110M
Cap. Flow
+$63.1M
Cap. Flow %
28.27%
Top 10 Hldgs %
78.3%
Holding
30
New
7
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$26.4M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$11.8M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$5.97M
4
HRTX icon
Heron Therapeutics
HRTX
+$3.71M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.82M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$6.99M
2
ACHC icon
Acadia Healthcare
ACHC
+$6.52M
3
TSRO
TESARO, Inc.
TSRO
+$3.74M
4
CARM
Carisma Therapeutics
CARM
+$931K
5
ARDM
Aradigm Corp Common Stock
ARDM
+$832K

Sector Composition

Rank Sector Weight
1 Healthcare 75.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
$36M 16.16%
1,000,000
+550,000
+122% +$11.8M
MDCO
2
DELISTED
Medicines Co
MDCO
$26.4M 11.84%
+700,000
New +$26.4M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$20.9M 9.39%
705,159
– –
MDCO
4
CALL
DELISTED
Medicines Co
MDCO
$20.7M 9.3%
+549,800
New +$20.7M
ONC
5
BeOne Medicines Ltd
ONC
$32.8B
$15.2M 6.82%
493,630
– –
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
$12.6M 5.63%
232,600
– –
AVXS
7
DELISTED
AveXis, Inc. Common Stock
AVXS
$12.4M 5.54%
299,756
+157,092
+110% +$5.97M
NGNE icon
8
Neurogene
NGNE
$656M
$11.7M 5.26%
43,888
– –
INCY icon
9
Incyte
INCY
$24.2B
$9.43M 4.23%
100,000
– –
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.6B
$9.25M 4.15%
100,000
+30,000
+43% +$2.82M
ARDM
11
DELISTED
Aradigm Corp Common Stock
ARDM
$6.4M 2.87%
930,513
-171,000
-16% -$832K
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.01M 2.25%
757,935
– –
RIGL icon
13
Rigel Pharmaceuticals
RIGL
$681M
$4.96M 2.22%
135,114
+65,114
+93% +$1.87M
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.69B
$3.55M 1.59%
234,220
– –
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$3.51M 1.57%
35,000
-40,000
-53% -$3.74M
HRTX icon
16
Heron Therapeutics
HRTX
$93.9M
$3.45M 1.54%
+200,000
New +$3.71M
KURA icon
17
Kura Oncology
KURA
$800M
$3.33M 1.49%
533,251
-100,441
-16% -$509K
ALDX icon
18
Aldeyra Therapeutics
ALDX
$92.9M
$2.29M 1.02%
291,230
– –
CARM
19
DELISTED
Carisma Therapeutics
CARM
$2.1M 0.94%
37,500
-12,500
-25% -$931K
EIGR
20
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.85M 0.83%
4,611
+1,500
+48% +$765K
ARRY
21
DELISTED
Array Biopharma Inc
ARRY
$1.35M 0.61%
+200,000
New +$774K
NBRV
22
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.25M 0.56%
707
– –
AKTX
23
Akari Therapeutics
AKTX
$13.8M
$1.19M 0.53%
175
– –
TRAW icon
24
Traws Pharma
TRAW
$6.85M
$838K 0.38%
+56
New +$1.14M
NVET
25
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$643K 0.29%
154,840
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Boxer Capital held 30 positions worth $223M, up 98% from $113M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Boxer Capital deployed $63.1M of net new capital in Q3 2016, opening 7 new positions and adding to 5 existing holdings. Its largest new stake was Medicines Co: 700,000 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was TESARO, Inc., an estimated $3.74M trimmed.

  • Boxer Capital's largest Q3 2016 buy was Medicines Co: 700,000 shares worth $26.4M.
  • Boxer Capital added most to Clovis Oncology, Inc. in Q3 2016, an estimated $11.8M increase.
  • Boxer Capital's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $3.74M.
  • Boxer Capital fully exited Regeneron Pharmaceuticals in Q3 2016, selling an estimated $6.99M.
  • Boxer Capital's ten largest holdings make up 78% of its $223M portfolio in Q3 2016.
  • Boxer Capital opened 7 new positions and closed 2 in Q3 2016.
  • Boxer Capital's portfolio value rose 98% quarter-over-quarter to $223M.

Based on Boxer Capital's 13F filing for Q3 2016, filed 14 Nov 2016.